Our partner is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, they have developed proprietary and highly differentiated ADC platforms and expertise to rapidly design and test novel ADCs and identify those with optimal efficacy, safety, and tolerability.

This hire built the regulatory CMC function and was a critical member of the regulatory leadership team. They helped advance assets from early to late stages of development and through major regulatory submissions to commercialization.